Drugs / CAR-37 T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04136275 | Jun 2020 → Sep 2023 | leukemia, non-Hodgkin lymphoma | Massachusetts General Hospital | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-37 T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04136275 ↗ |
| Known as | CAR-37 | “CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells” NCT04136275 ↗ |
| Action | Deplete | “CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells” NCT04136275 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor (CAR) T cells targeting CD37, an antigen highly expressed in B- and T-cell malignancies” PMID 38781564 ↗ Sep 2024 |
| Route | Intravenous | “CAR-37 will be administered intravenously on day 0” NCT04136275 ↗ |
| Target | CD37 | “chimeric antigen receptor (CAR) T cells targeting CD37, an antigen highly expressed in B- and T-cell malignancies” PMID 38781564 ↗ Sep 2024 |